{"schema":"sb.node.v1","id":"sb:e/3f51d2956f2ca1a58101e4be","kind":"entity","label":{"text":"nmpa","locale":"en"},"identity":{"anchor":"label:en:nmpa","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T15:58:04.276991+00:00","snapshot":"deploy 7e1a8471a23e0f1eb0285c67fee8a6f7d073739a"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":22,"separatePublishers":12,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.182: about 82% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto"],"activeDays":15,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/2a618c6668e3fa7b998c0f64","kind":"observation","label":"Clinical Trials Arena · 2026-09-20 · China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours","url":"https://www.clinicaltrialsarena.com/news/chinas-nmpa-akesos-ak158d1-trial/"},{"id":"sb:o/3b8c5befd13f379775fbe82a","kind":"observation","label":"AllSci News · 2026-10-07 · ArriVent's firmonertinib falls short in global Phase III EGFR exon 20 trial","url":"https://allsci.com/news/clinical-trials/furvent-trial-failure-stalls-firmonertinibs/"},{"id":"sb:o/c1a8e06d54fb32da183de029","kind":"observation","label":"Billboard Business · 2026-10-05 · The Next Battle Over Songwriter Streaming Royalties Has Begun. Don’t Expect a Quick Fight","url":"https://www.billboard.com/pro/songwriter-streaming-royalties-phono-v-rate-explained/"},{"id":"sb:o/d2b564991709d5aea6e4afc4","kind":"observation","label":"PR Newswire · 2026-10-02 · Úbytek hmotnosti o 19,3 % ve 48. týdnu: Na EASD byla představena studie fáze III zaměřené na regulaci tělesné hmotnosti s olatorepatidem od Hansoh","url":"https://www.prnewswire.com/news-releases/ubytek-hmotnosti-o-19-3--ve-48--tydnu-na-easd-byla-pedstavena-studie-faze-iii-zamene-na-regulaci-tlesne-hmotnosti-s-olatorepatidem-od-hansoh-302897146.html"},{"id":"sb:o/721033919e59ec7b34a4c86d","kind":"observation","label":"AllSci News · 2026-10-02 · Phrontline brings FRα×CDH6 dual-payload ADC into the clinic in China, US","url":"https://allsci.com/news/clinical-trials/tj102-ovarian-cancer-trial-phrontline-opens-phase/"},{"id":"sb:o/bc27c0d701fd0de208a4c237","kind":"observation","label":"CNBC · 2026-10-02 · Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion","url":"https://www.cnbc.com/2026/10/02/novartis-abogen-china-biotech-deal.html"},{"id":"sb:o/104df7a2f8f2dede3756ffdd","kind":"observation","label":"Memeburn · 2026-09-30 · The Honor Watch 6 Pro Doesn’t Measure Your Blood Sugar, and Its Cardiac Arrest Alert Isn’t the First of Its Kind","url":"https://memeburn.com/the-honor-watch-6-pro-doesnt-measure-your-blood-sugar/"},{"id":"sb:o/58502a34080332e5e1cdf43b","kind":"observation","label":"newindianexpress · 2026-09-30 · Massive explosion at MRPL refinery in Mangaluru triggers panic; rescue operations underway","url":"https://www.newindianexpress.com/states/karnataka/2026/Sep/30/massive-explosion-at-mrpl-refinery-in-mangaluru-triggers-panic-rescue-operations-underway"},{"id":"sb:o/f6ae7a8560c44cac91d25942","kind":"observation","label":"Clinical Trials Arena · 2026-09-28 · Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC","url":"https://www.clinicaltrialsarena.com/news/innovent-marslight-11-trial-non-squamous-nsclc/"},{"id":"sb:o/064561f300ab767c45a3995e","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-28 · Innovent Expands Phase 3 MarsLight-11 Trial of IBI363/TAK-928 to Non-Squamous NSCLC","url":"https://www.clinicaltrialvanguard.com/news/innovent-expands-phase-3-marslight-11-trial-of-ibi363-tak-928-to-non-squamous-nsclc/"}],"cursor":"c1.eyJpZCI6InNiOmUvM2Y1MWQyOTU2ZjJjYTFhNTgxMDFlNGJlIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDE1OjU4OjA0LjI3Njk5MSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":3,"byKind":{"co-mentioned":3},"items":[{"kind":"relation","label":"co-mentioned with china (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c0422e17760b6cf2808a7be0"},{"kind":"relation","label":"co-mentioned with fda (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2fb7bd728154a905cce6bbd3"},{"kind":"relation","label":"co-mentioned with clinical trial (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4db6a8150ec3ca27a8bebef1"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/3f51d2956f2ca1a58101e4be","mcp":"traverse {\"id\":\"sb:e/3f51d2956f2ca1a58101e4be\"}","page":"/entity/nmpa/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/3f51d2956f2ca1a58101e4be\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/3f51d2956f2ca1a58101e4be\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/3f51d2956f2ca1a58101e4be\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/3f51d2956f2ca1a58101e4be\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}